Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molixan in Severe COVID-19
NCT04780672Phase 3Unknown
- Sponsor
- Pharma VAM
- Start
- Mar 2021
- Primary completion
- May 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NOV-205 in coronavirus disease 2019 (COVID-19), sponsored by Pharma VAM. Status: unknown.
02
Drugs
NOV-205
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04780672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780672.